<DOC>
	<DOCNO>NCT00379457</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . It yet know combination chemotherapy regimen effective treat rhabdomyosarcoma . PURPOSE : This randomized phase III trial study different combination chemotherapy regimens compare well work treat young patient nonmetastatic rhabdomyosarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients With Nonmetastatic Rhabdomyosarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Improve outcome pediatric patient low-risk rhabdomyosarcoma ( RMS ) treat vincristine dactinomycin alone . - Evaluate whether outcome old patient standard-risk RMS favorable feature may improved/maintained administer treatment limited intensity . - Evaluate whether chemotherapy intensity patient standard-risk RMS reduce , lower cumulative dose ifosfamide . - Evaluate whether treatment reduce subgroup patient standard-risk RMS arise unfavorable site ( e.g. , parameningeal site ) favorable site age . - Compare value standard chemotherapy comprise ifosfamide , vincristine , dactinomycin v without doxorubicin ( early intensification initial part treatment ) patient high-risk RMS . - Determine role low-dose maintenance chemotherapy comprise 6 month cyclophosphamide vinorelbine patient high-risk RMS . - Improve result patient poor prognosis ( high-risk ) RMS treat intensive ifosfamide , vincristine , dactinomycin , doxorubicin follow maintenance chemotherapy . OUTLINE : This non-blinded , randomize , prospective , multicenter study . Patients stratify accord risk group ( low risk v standard risk vs high risk vs high risk ) participate country . - Stratum 1 ( low-risk group ) : Patients receive vincristine IV day 1 week 1-4 , 7-10 , 13-16 , 19-22 dactinomycin IV day 1 week 1 , 4 , 7 , 10 , 13 , 16 , 19 , 22 . - Stratum 2 ( standard-risk group ) : Patients assign 1 3 treatment group accord standard-risk subgroup . - Subgroup B : Patients receive ifosfamide IV 3 hour day 1 2 week 1 , 4 , 7 , 10 ; vincristine IV day 1 week 1-7 , 10 , 13 , 16 , 19 , 22 , 25 ; dactinomycin IV day 1 week 1 , 4 , 7 , 10 , 13 , 16 , 19 , 22 , 25 . - Subgroup C : Patients receive ifosfamide IV 3 hour day 1 2 week 1 , 4 , 7 ; vincristine IV day 1 week 1-7 ; dactinomycin IV day 1 week 1 , 4 , 7 . Patients evaluate tumor response week 9 . Patients complete remission ( CR ) favorable age tumor size continue receive ifosfamide , vincristine , dactinomycin week 10 , 13 , 16* , 19 , 22 , 25 . Patients may also undergo radiotherapy begin week 13 continue 5-6 week . Patients CR unfavorable age tumor size OR partial remission ( PR ) ( i.e. , &gt; 1/3 tumor volume reduction ) continue receive ifosfamide week 10 16 vincristine dactinomycin week 10 , 13 , 16* , 19 , 22 , 25 . These patient also undergo radiotherapy begin week 13 continue 5-6 week . Patients stable progressive disease week 9 proceed second-line therapy radiotherapy . Patients residual disease completion chemotherapy week 10 undergo surgical resection follow ifosfamide , vincristine , dactinomycin ( without radiotherapy ) week 13 , 16* , 19 , 22 , 25 . - Subgroup D : Patients receive ifosfamide IV 3 hour day 1 2 week 1 , 4 , 7 ; vincristine IV day 1 week 1-7 ; dactinomycin IV day 1 week 1 , 4 , 7 . Patients evaluate tumor response week 9 . Patients CR PR continue receive ifosfamide , vincristine , dactinomycin week 10 , 13 , 16* , 19 , 22 , 25 . Patients may also undergo radiotherapy begin week 13 continue 5-6 week . Patients stable progressive disease week 9 proceed second-line therapy radiotherapy . Patients residual disease completion chemotherapy week 10 undergo surgical resection follow ifosfamide , vincristine , dactinomycin ( without radiotherapy ) week 13 , 16* , 19 , 22 , 25 . NOTE : *Dactinomycin may omit radiotherapy week 16 . - Stratum 3 ( high-risk group ) : Patients randomize 1 2 treatment arm . - Arm I : Patients receive ifosfamide , vincristine , dactinomycin subgroup C D stratum 2 . Patients evaluate tumor response week 9 . Patients CR PR continue receive ifosfamide , vincristine , dactinomycin subgroup C D stratum 2 . Patients may also undergo radiotherapy begin week 13 continue 5-6 week . Patients stable progressive disease week 9 proceed second-line therapy radiotherapy . Patients residual disease completion chemotherapy week 10 undergo surgical resection follow ifosfamide , vincristine , dactinomycin ( without radiotherapy ) week 13 , 16* , 19 , 22 , 25 . - Arm II : Patients receive ifosfamide , vincristine , dactinomycin subgroup C D stratum 2 . Patients also receive doxorubicin IV 4 hour day 1 2 week 1 , 4 , 7 . Patients evaluate tumor response week 9 . Patients CR PR continue receive ifosfamide , vincristine , dactinomycin , doxorubicin week 10 ifosfamide , vincristine , dactinomycin week 13 , 16* , 19 , 22 , 25 . Patients may also undergo radiotherapy begin week 13 continue 5-6 week . Patients stable progressive disease week 9 proceed second-line therapy radiotherapy . Patients residual disease completion chemotherapy week 10 undergo surgical resection follow ifosfamide , vincristine , dactinomycin ( without radiotherapy ) week 13 , 16* , 19 , 22 , 25 . NOTE : *Dactinomycin may omit radiotherapy week 16 . - Maintenance chemotherapy : Patients remain CR minimal abnormality image study completion therapy accord randomize arm ( ) undergo second randomization . Randomization occur within 6 week administration last course chemotherapy arm I II . - Arm I : Patients receive maintenance chemotherapy . - Arm II : Patients receive vinorelbine IV 5-10 minute day 1 , 8 , 15 oral cyclophosphamide daily day 1-28 . Treatment repeat every 28 day 6 course . - Stratum 4 ( high-risk group ) : Patients receive ifosfamide , vincristine , dactinomycin subgroup C D stratum 2 . Patients also receive doxorubicin arm II stratum 3 . Patients evaluate tumor response week 9 . Patients CR PR continue receive ifosfamide , vincristine , dactinomycin , doxorubicin arm II stratum 3 . Patients may also undergo radiotherapy begin week 13 continue 5-6 week . Patients stable progressive disease week 9 proceed second-line therapy radiotherapy . Patients residual disease completion chemotherapy week 10 undergo surgical resection follow ifosfamide , vincristine , dactinomycin ( without radiotherapy ) week 13 , 16 , 19 , 22 , 25 . After completion chemotherapy , patient limit quantity viable tumor proceed maintenance chemotherapy . - Maintenance chemotherapy : Patients receive vinorelbine IV 5-10 minute day 1 , 8 , 15 oral cyclophosphamide daily day 1-28 . Treatment repeat every 28 day 6 course . - Second-line therapy : Patients stratum stable progressive disease week 9 receive 1 2 second-line therapy regimen . - Regimen 1 : Patients receive topotecan IV day 1-3 carboplatin IV day 4 5 week 1 4 . Patients evaluate tumor response . Patients good response receive topotecan IV day 1-3 cyclophosphamide IV day 1 2 week 7 13 etoposide IV day 1-3 carboplatin IV day 4 5 week 10 16 . Patients response receive local therapy new chemotherapy regimen . - Regimen 2 : Patients receive doxorubicin IV day 1 carboplatin IV day 1 2 week 1 4 . Patients evaluate tumor response . Patients good response receive doxorubicin IV day 1 week 7 , 10 , 13 , 16 ; cyclophosphamide IV day 1 2 week 7 13 ; carboplatin IV day 1 2 week 10 16 . Patients response receive local therapy new chemotherapy regimen . After completion therapy , patient follow periodically least 5 year . PROJECTED ACCRUAL : A total 600 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm rhabdomyosarcoma ( RMS ) malignant mesenchymal tumor , include undifferentiated soft tissue sarcoma ectomesenchymoma Has undergone diagnostic surgery within past 8 week Meets criteria 1 follow risk group : Lowrisk group Localized nonalveolar RMS site Embryonal , spindle cell , botryoid RMS ( favorable pathology ) Microscopically completely resect disease ( Intergroup Rhabdomyosarcoma Study [ IRS ] group I ) Negative node ( N0 ) Tumor size ≤ 5 cm AND age &lt; 10 year ( favorable tumor size age ) Standardrisk group , meet criterion 1 follow subgroup : Subgroup B Localized nonalveolar RMS site Favorable pathology Microscopically completely resect disease ( IRS group I ) N0 disease Tumor size &gt; 5 cm OR age ≥ 10 year ( unfavorable tumor size age ) Subgroup C Localized nonalveolar RMS orbit , head neck nonparameningeal site , genitourinary ( GU ) non bladder prostate ( i.e. , paratesticular vagina/uterus ) sit ( favorable site ) Favorable pathology Microscopic residual disease ( pT3a ) completely resect disease nodal involvement ( N1 ) ( IRS group II ) OR macroscopic residual disease ( pT3b ) ( IRS group III ) N0 disease Any tumor size age Subgroup D Localized nonalveolar RMS parameningeal site , extremity , GU bladder prostate site , site ( unfavorable site ) Favorable pathology IRS group II III N0 disease Favorable tumor size age Highrisk group , meet criterion 1 follow subgroup : Subgroup E Localized nonalveolar RMS unfavorable site Favorable pathology IRS group II III N0 disease Unfavorable tumor size age Subgroup F Localized nonalveolar RMS site Favorable pathology IRS group I , II , III Positive node ( N1 ) Any tumor size age Subgroup G Localized alveolar RMS site Alveolar RMS , include solidalveolar variant ( unfavorable pathology ) IRS group I , II , III N0 disease Any tumor size age Very highrisk group Localized alveolar RMS site Unfavorable pathology IRS group I , II , III N1 disease Any tumor size age Previously untreated disease ( except primary surgery ) No evidence metastatic disease PATIENT CHARACTERISTICS : Shortening fraction &gt; 28 % Ejection fraction &gt; 47 % No prior cardiac disease Renal function must equivalent grade 01 nephrotoxicity No prior malignant tumor No preexist illness prevent treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>alveolar childhood rhabdomyosarcoma</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
	<keyword>childhood malignant mesenchymoma</keyword>
	<keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
	<keyword>embryonal childhood rhabdomyosarcoma</keyword>
	<keyword>embryonal-botryoid childhood rhabdomyosarcoma</keyword>
</DOC>